Drug intelligence / Profile preview

aminoglutethimide + danazol + medroxyprogesterone acetate + tamoxifen

Development stage: Unknown
Lead developer: Winthrop Company
Modality: Small Molecules
Administration: Oral, Intramuscular

Overview

A combination of four hormonal therapy agents used in cancer treatment. This combination includes aminoglutethimide (an aromatase inhibitor), danazol (a synthetic androgen), medroxyprogesterone acetate (a progestin), and tamoxifen (a selective estrogen receptor modulator). Each component works through different mechanisms to modulate hormone activity, particularly in hormone-dependent cancers.

Targets

ER (Estrogen receptor)CYP11A1 (Cholesterol side chain cleavage enzyme)CYP19A1 (Aromatase)PR (Progesterone receptor)AR (Adrenergic receptors)

Beyond the preview

Go deeper on aminoglutethimide + danazol + medroxyprogesterone acetate + tamoxifen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aminoglutethimide + danazol + medroxyprogesterone acetate + tamoxifen.

Explore the full profile